Background. Vasopressin analog Terlipressin use is the most effective approach for the management of hepatorenal syndrome. Hepatorenal syndrome and ovarian hyperstimulation syndrome shares a common clinical sign, which is ascites, although the underlying mechanism is different; we suggest that terlipressin could be used for OHSS prevention. Objectives. This study was designed to evaluate the effects of terlipressin use on OHSS prevention in a rodent model of OHSS. Method. Mice were divided into tree groups - one was a control group (n=5) with no intervention and two experimental (1st group n=12, 2nd group=15). The animals in a control group were at the stage of estrus, which corresponds to the spontaneous ovulation. Animals in both experimental groups received a hormonal stimulation with gonadotropins - 20 IU of pregnant mare serum gonadotropin (PMSG) and after 48 hours - 20 IU of human chorionic gonadotropin (hCG). Additionally animals from second experimental group received terlipressin 4.8 mg immediately after hCG administration and 3 hours after. Results. Ovarian stimulation with our protocol led to the development of several OHSS symptoms features: swelling of the ovaries, increase in their size, hyperemia and presence of hemorrhagic follicles as compared to control. On the sixth day of observation in the group of animals treated with terlipressin there was reduction in ovarian size comparable to control group and morphological improvement in ovarian parenchyma, which was not observed in animals who did not received terlipressin. Conclusion. It was shown that terlipressin administration in mice model of OHSS provides marked therapeutic action and accelerates ovary recovery rate and folliculogenesis restoration. The possible mechanism of terlipressin action is to be considered.